In a pre-clinical model of CAR-T therapy, the addition of ibrutinib significantly reduced serum cytokines associated with CRS including IFNγ, IL-6, TNFα, IL-2, and GM-CSF [20]. The gene discussed is IL2; the disease is congenital rubella syndrome.